Interviews

Aspect Biosystems

2024-04-26

Aspect Biosystems is currently experiencing a period of strategic growth, focusing on expanding our therapeutic pipeline in the metabolic and endocrine space.

Terrie Curran

Phathom Pharma

2024-04-26

Our ambitious clinical program aims to expand treatment options for various GERD-related conditions, demonstrating our commitment to addressing unmet needs in gastrointestinal care.

Quentin Blackford

iRhythm Technologies

In the next five years, I envision iRhythm playing a pivotal role in detecting, predicting, and preventing disease on a global scale. While our initial focus was on cardiac health, our future includes expanding into adjacent markets like sleep disorders, hypertension, and heart failure.

Ken Mariash

Sinaptica

The term "breakthrough" is overused, yet in my two decades of experience in Alzheimer's research, I have never encountered placebo-controlled efficacy data as compelling as what we've observed at Sinaptica.

Holly Sheffield

President

CooperSurgical

Our differentiation lies in supporting women throughout their life cycle, having a presence in various healthcare settings where women seek care. From contraception to conception and through labor and delivery, we’re part of the entire journey.

John Crowley

Biotechnology Innovation Organization (BIO)

We're witnessing an unprecedented convergence of biotechnologies with other technological advancements, promising significant progress in human health, climate change mitigation, and food security.

Ivan Tornos

Zimmer Biomet

We believe ZB’s opportunities in the orthopedics space far outweigh the challenges. We're expanding into ASCs, leveraging our expertise in delivering efficiency and safety, which are especially critical in these settings.

Peter Halling

ALK

ALK is focusing on treating the allergic disease with the so-called allergy immunotherapy also known as AIT. AIT is a treatment approach, where the person with medium to severe allergy is typically going through a three-year treatment, where the treatment aims at training the body’s immune response not to overreact to allergens.

Florian Brand

atai Life Sciences